Ironwood, Allergan add a slate of PhIIIb data to its Linzess pitch for physicians, patients
With the dust settled on an R&D spinout, the fully commercial operations at Ironwood have come up with some late-stage data to up its Linzess marketing game.
Ironwood, along with partner Allergan, set out to collect evidence that their drug can improve the overall abdominal symptoms of irritable bowel syndrome with constipation (IBS-C), not just constipation. And the companies say that’s what they found in the Phase IIIb: Patients taking Linzess for 12 weeks saw a 29.7% mean decrease from baseline in a weekly score that measured bloating, pain and discomfort, compared to 18.3% for placebo (p<0.0001).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.